Categories
Pages
- Isoprotrace brochure download
- Isoprotrace – DE
- Isoprotrace ®
- Isotopia Europe (Seibersdorf)
- Our Sites
- Aseptic plant
- Isoprotrace-NL
- Isotopia USA
- FAPI Study Request
- Welcome to our FAPI site
- FAPI Articles
- Lu177 Treatments
- Privacy Policy
- Theranostics
- Radiopharmacy
- Products
- PET Products
- SPECT Products
- Services
- Cold Kits
- Radiopharmaceuticals Companies
- Partnerships & Distribution
- Our Customers
- Regulation and Quality
- Home
- Contact us
- IsoBlog
- Theranostics + Targeted Therapy
- LuPARP
- Careers
- Product Safety
- Testimonials
- Investors
- Our values
- Company profile
- Our Management Team
- News
- Sample request
- Lu177
News & Info
- Hanukkah 2019 – Family day at Isotopia
- Marking International Parkinson’s Disease Day: The Power of [18F]-FDOPA PET/CT in Diagnosis
- UK Launch PR
- Isotopia Announces Official Commercial Launch of Isoprotrace® in Germany in Partnership with DSD Pharma
- Isoprotrace® Receives Marketing Authorization in Denmark
- Kinectrics and Isotopia Enter Agreement for Supply of Gadolinium-160 (Gd-160) to Support Production of Terbium-161 (Tb-161)
- THE CLINICAL UTILITY OF PSMA-11
- The Role of Aseptic Manufacturing in Ensuring Drug Safety
- Breakthrough in Lupus Treatment: Isotopia Partners with LIVEKIDNEY.BIO
- Quality Assurance Pharmacist
- Isotopia Molecular Imaging Ltd. to Showcase Innovation in Targeted Radiopharmaceuticals at the TRP Summit
- PSMA-11: The Gold Standard in Prostate Cancer Imaging
- Isoprotrace® Officially Approved in the Netherlands
- Isoprotrace – DE
- Isotopia is exhibiting at the EANM 2024 conference in Hamburg from October 19-23 at Booth H45. Let’s connect!
- Immunity Pharma Ltd (IPL) & Isotopia Molecular Imaging Ltd Signed a Strategic Agreement for Clinical Contract Manufacturing Services
- Unveiling the Significance of SUV Measure in Theranostics
- Isoprotrace® received marketing authorization in the Netherlands
- Isotopia USA partners with E Solutions and Comfort Systems
- Nuclear Medicine role in Neuroendocrine Tumors
- Production Technician – Lutetium
- Terbium 161 for Targeted Radionuclide Therapy in Oncology
- Terbium-161 Radionuclide Therapy in Prostate Cancer
- Radiopharmacy and Radiobiology Aspects for 161-Terbium
- The Future of Theranostics in Prostate Cancer- PSMA RLT and Combination Therapy
- Todd Hockemeyer, CEO- Isotopia USA
- Isotopia is expanding its global footprint after filling a DMF in the US FDA and MF in Canada
- Is there a future for PSMA theranostics in Osteosarcoma?
- Successful implementation of a GMP-compliant eQMS solution
- PSMA theranostics in tumors other than prostate cancer
- Pilochem AG, Seibersdorf Labor GmbH and Isotopia announce supply, development, and manufacturing agreements
- Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement
- Advancing clinical journey with our partners
- Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers
- 6th Theranostics World Congress- June 24-26, 2022- Wiesbaden, Germany
- SNMMI 2022 annual meeting, 11-14, in Vancouver, Canada
- We are looking for a VP of sales in Europe
- Nuclear imaging in Parkinson’s disease- The past, the present, and the future
- Overcoming Lutetium-177 Production and Supply Challenges
- National Comprehensive Cancer Network® (NCCN) Guidelines® Version 03/2022
- Isotopia Molecular Imaging and Sinotau Pharmaceuticals Sign a Clinical Supply Agreement for 177Lu n.c.a
- Isotopia and the Peter MacCallum Cancer Center announce Terbium-161 clinical study collaboration
- Isotopia and Seibersdorf Labor GmbH Announce Production Agreement for 177Lu n.c.a
- Isotopia and FutureChem sign a clinical supply agreement for 177Lu n.c.a
- HERMES MEDICAL SOLUTIONS & ISOTOPIA ANNOUNCE A NEW COLLABORATION FOCUSED ON DOSIMETRY
- POINT Biopharma and Isotopia Announce Lutetium-177 Clinical Supply Agreement
- Getting to know Isotopia’s supply chain
- Elgan Pharma and Isotopia Molecular Imaging Signed on a Strategic agreement for Phase III and commercial Contract Manufacturing Services
- Israeli researchers developing radioactive marker to detect small, aggressive cancerous tumors
- Jubilant Radiopharma and Isotopia Molecular Imaging Enter into a Strategic Partnership to Further Advance the Field of Radiotherapeutics
- Isotopia and M.T.T.I signed for the supply of Lu-177 n.c.a
- Breaking news !
- ARTMS and Isotopia Announce successful Multi-Curie Labeling of PSMA-11
- Isotopia begins clinical supply collaboration with Y-mAbs Therapeutics,Inc
- Isotopia and CPDC Announce Production Agreement for n.c.a. Lu-177
- Isotopia files Drug Master File (DMF) with the U.S. Food and FDA for Lu177 n.c.a
- Vision study – Research on Prostate Cancer
- proPSMA study
- COVID-19 measures – Isotopia Molecular Imaging
- Isotopia’s announcement: GMP certificate was given for Lu177 chloride
- Isotopia and Eckert & Ziegler to start Partnership for Prostate Cancer Imaging
- 18F-DOPA use in Parkinsonism
- Lutetium 177 production (Lu177 production)
- PERSONALIZED NUCLEAR MOLECULAR CANCER THERAPY
- Prostate cancer
- CNIC establishes global partnership with Isotopia to put patients first
- Tech transfer for isoPROtrace-11 completed
- EANM 2019 Barcelona
- FDA inspection
- Lu-177 n.c.a status update
- The first Radio-pharmacy GPP certified
- Israeli Nuclear Medicine Conference INM
- Isotopia completes the acquisition of the pharmaceutical aseptic plant located in soreq
- Isotopia participated in the PDA convention
- 15th Annual Update Conference on Clinical Neurology & Neurophysiology
- F-DOPA reimbursed for Israeli patients
- EANM 2018 Germany
- Isotopia starts Lu-177 c.a
